Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Cipriani, Sabrina ^a   Renga, Barbara ^a   D'Amore, Claudio ^a   Simonetti, Michele ^a   De Tursi, Antonio Angelo ^a   Carino, Adriana ^a   Monti, Maria Chiara ^b   Sepe, Valentina ^c   Zampella, Angela ^c   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; 6ALPHA ETHYL 3ALPHA 7ALPHA DIHYDROXY 24 NOR 5BETA CHOLAN 23 OL; ALKALINE PHOSPHATASE; BETULIC ACID; BILE ACID; BILE SALT EXPORT PUMP; CHENODEOXYCHOLIC ACID; DEOXYCHOLIC ACID; ETHINYLESTRADIOL; FARNESOID X RECEPTOR; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; LIGAND; MULTIDRUG RESISTANCE PROTEIN 1; OBETICHOLIC ACID; PROTEIN TYROSINE PHOSPHATASE SHP; UNCLASSIFIED DRUG; CELL RECEPTOR; CHOLANE DERIVATIVE; ESTROGEN; FARNESOID X-ACTIVATED RECEPTOR; GPBAR1 PROTEIN, MOUSE; ISOTHIOCYANIC ACID; ISOTHIOCYANIC ACID DERIVATIVE;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PRURITUS; SIGNAL TRANSDUCTION; SURVIVAL; ANIMAL; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DEFICIENCY; DISEASE MODEL; GENE DELETION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TOXIC HEPATITIS;

ANIMALS; BILE ACIDS AND SALTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHOLANES; CHOLESTASIS; DISEASE MODELS, ANIMAL; ESTROGENS; GENE DELETION; ISOTHIOCYANATES; LIGANDS; MALE; MICE; PRURITUS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84941338314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129866     Document Type: Article

References (43)

1. Hirschfield GM, Chapman RW, Karlsen TH, Lammert F, Lazaridis KN, Mason AL. The genetics of complex cholestatic disorders. Gastroenterology 2013; 144:1357-1374. doi: 10.1053/j.gastro.2013.03.053 PMID: 23583734
2. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol 2013; 7:103-114. doi: 10.1586/egh.12.80 PMID: 23363260
3. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013; 145(3):521-36. doi: 10. 1053/j.gastro.2013.06.052 PMID: 23827861
4. Sinakos E, Samuel S, Enders F, Loftus EV Jr., Sandborn WJ, Lindor KD. Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship. Inflamm Bowel Dis 2013; 19:1004-1009. doi: 10.1097/MIB.0b013e3182802893 PMID: 23502353
5. Poupon R. Ursodeoxycholic acid and bile-Acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36:S3-S12. doi: 10.1016/S2210-7401(12)70015-3 PMID: 23141891
6. Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, et al. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int 2007; 27:920-929. PMID: 17696930
7. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A. Bile acid-Activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res. 2010; 49:171-185. doi: 10.1016/j.plipres.2009.11.001 PMID: 19932133
8. Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F. Targeting FXR in cholestasis: hype or hope. Exp Opin Ther Targets 2014; doi: 10.1517/14728222.2014.956087
9. Renga B, Migliorati M, Mencarelli A, Cipriani S, D'Amore C, Distrutti E, et al. Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter. Biochim Biophys Acta 2011; 180:157-165.
10. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, Kim CS, et al. Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2002; 2:721-731. PMID: 12062085
11. Wagner M, Fickert P, Zollner G, Fuchsbichler A, Silbert D, Tsybrovskyy O, et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology 2003; 125:825-838. PMID: 12949728
12. Fiorucci S, Baldelli F. Farnesoid receptor agonists in biliary tract disease. Curr Opin Gastroenterol 2009; 25:252-259. doi: 10.1097/MOG.0b013e328324f87e PMID: 19300246
13. Stedman C, Liddle C, Coulter S, Sonoda J, Alvarez JG, Evans RM,et al. Benefit of farnesoid X receptor inhibition in obstructive cholestasis. Proc Natl Acad Sci USA 2006; 103:11323-11328. PMID: 16844773
14. Marschall HU, Wagner M, Bodin K, Zollner G, Fickert P, Gumhold J, et al. Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res 2006; 47:582-592. PMID: 16327028
15. Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in choelstasis. J Steroid Biochem Mol Biol 2012; 130:147-158. doi: 10.1016/j.jsbmb.2011.06.012 PMID: 21801835
16. Renga B, Mencarelli A, D'Amore C, Cipriani S, D'Auria MV, Sepe V, et al. Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. PLoS One 2012; 7:e30443. doi: 10.1371/journal.pone.0030443 PMID: 22291955
17. Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev Med Chem. 2011; 11:753-762. PMID: 21707532
18. Kowdley KV, Jones D, Luketic V, Chapman R, Burroughs A, Hirschfield G et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC (Abstract). J Hepatol 2011; 54: S13.
19. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45:17:3569-3572. PMID: 12166927
20. Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127:1497-1512. PMID: 15521018
21. D'Amore C, Di Leva FS, Sepe V, Renga B, Del Gaudio C, D'Auria MV,et al. Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. J Med Chem 2014; 57:937-54 doi: 10.1021/jm401873d PMID: 24387325
22. Maruyama T, Miyamoto Y, Nakamura T, Tamai Y, Okada H, Sugiyama E, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Bophys Res Commun 2002; 298:714-719.
23. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M,et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278:9435-9440. PMID: 12524422
24. Fiorucci S, Mencarelli A, Palladino G, Cipriani S. Bile-Acid-Activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. Trends Pharmacol Sci 2009; 30:570-580. doi: 10. 1016/j.tips.2009.08.001 PMID: 19758712
25. Keitel V, Cupisti K, Ullmer C, Knoefel WT, Kubitz R, Haussinger D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009; 50:861-870. doi: 10.1002/hep.23032 PMID: 19582812
26. Keitel V, Donner M, Winandy S, Kubitz R, Haussinger D. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008; 372:78-84. doi: 10.1016/j.bbrc.2008. 04.171 PMID: 18468513
27. Alemi F, Kwon E, Poole DP, Lieu T, Lyo V, Cattaruzza F, et al. The TGR5 receptor mediates bile acidinduced itch and analgesia. J Clin Invest 2013; 123:1513-1530. doi: 10.1172/JCI64551 PMID: 23524965
28. Festa C, Renga B, D'Amore C et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GPBAR1) ligands. J Med Chem, 2014. doi: 10.1021/jm501273r
29. Leva FS, Festa C, D'Amore C, De Marino S, Renga B, D'Auria MV, et al. Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. J Med Chem. 2013; 56: 4701-17 doi: 10.1021/jm400419e PMID: 23656455
30. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005; 313: 604-612. PMID: 15644430
31. Mencarelli A, Renga B, D'Amore C, Santorelli C, Graziosi L, Bruno A, ei al. Dissociation of intestinal and hepatic activities of FXR and LXR? supports metabolic effects of terminal ileum interposition in rodents. Diabetes 2013; 62:3384-3393. doi: 10.2337/db13-0299 PMID: 23835330
32. Fagan EA. Intrahepatic cholestasis of pregnancy. Clin Liver Dis 1999; 3:603-632. PMID: 11291241
33. Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003; 17:857-870. PMID: 12656688
34. Schoenfield LJ, Sjorvall J, Perman E. Bile acids on the skin of patients with pruritic hepatobiliary disease. Nature 1967; 213:93-94.
35. Kirby J, Heaton KW, Burton JL. Pruritic effect of bile salts. Br Med J 1974; 4:693-695. PMID: 4441863
36. Varadi DP. Pruritus induced by crude bile and purified bile acids. Experimental production of pruritus in human skin. Arch Dermatol 1974; 109:678-681. PMID: 4828535
37. Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010; 139:1008-1018. doi: 10.1053/j. gastro.2010.05.009 PMID: 20546739
38. Lieu T, Jayaweera G, Zhao P, Poole DP, Jensen D, Grace M, et al. The Bile Acid Receptor TGR5 Activates the TRPA1 Channel to Induce Itch in Mice. Gastroenterology 2014 doi: 10.1053/j.gastro.2014.08. 042
39. Jensen DD, Godfrey CB, Niklas C, Canals M, Kocan M, Poole DP, et al. The bile acid receptor TGR5 does not interact with ?-Arrestins or traffic to endosomes but transmits sustained signals from plasma membrane rafts. J Biol Chem. 2013; 288:22942-60 doi: 10.1074/jbc.M113.455774 PMID: 23818521
40. Ruparel NB, Patwardhan AM, Akopian AN, Hargreaves KM. Desensitization of transient receptor potential ankyrin 1 (TRPA1) by the TRP vanilloid 1-selective cannabinoid arachidonoyl-2 chloroethanolamine. Mol Pharmacol. 2011; 80:117-23 doi: 10.1124/mol.110.068940 PMID: 21441412
41. Braz J, Solorzano C, Wang X, Basbaum AI. Transmitting pain and itch messages: a contemporary view of the spinal cord circuits that generate gate control. Neuron 2014; 82: 522-536. doi: 10.1016/j.neuron. 2014.01.018 PMID: 24811377
42. LaMotte RH, Dong X, Ringkamp M. Sensory neurons and circuits mediating itch. Nat Rev Neurosci 2014; 15:19-31. doi: 10.1038/nrn3641 PMID: 24356071
43. LI T, Holmstrom SR, Kir S, Umetani M, Schmidt DR, Kleiwer SA, et al. The G protein coupled bile acid receptor, TGR5, stimulates gallbladder filling. Mol Endocrinol 2011; 25: 1066-1071. doi: 10.1210/me. 2010-0460 PMID: 21454404